secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001140361-24-010920
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio licenses acoramidis to Bayer for EU rights; up to $310M milestones plus royalties
--------------------------------------------------------------------------------

- Eidos grants Bayer exclusive license to develop/commercialize acoramidis (AG10) for ATTR amyloidosis in EU and European Patent Organization.
- BridgeBio eligible for up to $310M in upfront, regulatory, and sales milestone payments through 2026.
- Additional payments subject to achievement of further sales milestones.
- Tiered royalties starting in low-thirties percent on net sales in Licensed Territory.
- Agreement subject to antitrust clearance; termination rights for material breach, insolvency, or Bayer convenience (270 days' notice).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124010920/0001140361-24-010920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124010920/ef20022786_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-010920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer